Drug executives list pros, cons of health reform

11/18/2009 | Wall Street Journal, The

Health reform legislation could increase drug benefits and decrease the cost of medications, potentially improving the public's perception of the pharmaceutical industry, said Jane Horvath, Merck & Co.'s senior director of public policy. However, the bill could mean more contribution from the industry through "Medicaid-style rebates" and also compromise relationships with academic researchers, said Horvath, whose concerns were echoed by other drug executives at a biotech conference in Philadelphia.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA